Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $38.50.

Several brokerages have recently weighed in on ALGS. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Weiss Ratings raised Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Finally, Lake Street Capital started coverage on Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 price target on the stock.

Aligos Therapeutics Stock Performance

Shares of ALGS stock opened at $6.91 on Friday. The firm has a market capitalization of $43.12 million, a price-to-earnings ratio of -0.95 and a beta of 2.31. The company has a 50 day moving average price of $5.87 and a 200 day moving average price of $6.33. Aligos Therapeutics has a one year low of $3.98 and a one year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.95. The company had revenue of $27.78 million during the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. As a group, equities analysts forecast that Aligos Therapeutics will post -6.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently bought and sold shares of ALGS. Rockefeller Capital Management L.P. raised its holdings in shares of Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after acquiring an additional 9,000 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Aligos Therapeutics during the 3rd quarter valued at about $99,000. XTX Topco Ltd acquired a new position in Aligos Therapeutics during the second quarter worth $100,000. HRT Financial LP bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at approximately $106,000. Finally, DRW Securities LLC bought a new position in shares of Aligos Therapeutics in the fourth quarter worth about $111,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.